These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 26011651

  • 1. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [Abstract] [Full Text] [Related]

  • 2. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G.
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [Abstract] [Full Text] [Related]

  • 3. Mesothelioma cells breaking bad: loss of integrin α7 promotes cell motility and poor clinical outcomes in patients.
    Burkin DJ, Fontelonga TM.
    J Pathol; 2015 Nov; 237(3):282-4. PubMed ID: 26174987
    [Abstract] [Full Text] [Related]

  • 4. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
    Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G.
    J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma.
    Mairinger FD, Walter RF, Ting S, Vollbrecht C, Kollmeier J, Griff S, Hager T, Mairinger T, Christoph DC, Theegarten D, Schmid KW, Wohlschlaeger J.
    Future Oncol; 2014 May; 10(6):995-1005. PubMed ID: 24941985
    [Abstract] [Full Text] [Related]

  • 10. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L, Tounsi A, Berenguer-Daizé C, Dussault N, Delfino C, Benyahia Z, Cayol M, Mabrouk K, Garcia S, Martin PM, Barlesi F, Ouafik L.
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [Abstract] [Full Text] [Related]

  • 11. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
    Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G.
    Mol Cancer; 2016 Jun 01; 15(1):44. PubMed ID: 27245839
    [Abstract] [Full Text] [Related]

  • 12. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G.
    Br J Cancer; 2019 Feb 01; 120(4):387-397. PubMed ID: 30739911
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld J, Iorio F, Kolluri K, Garnett M, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C.
    Clin Cancer Res; 2018 Jan 01; 24(1):84-94. PubMed ID: 29061644
    [Abstract] [Full Text] [Related]

  • 15. Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma.
    Tranchant R, Quetel L, Tallet A, Meiller C, Renier A, de Koning L, de Reynies A, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Jean D.
    Clin Cancer Res; 2017 Jun 15; 23(12):3191-3202. PubMed ID: 28003305
    [Abstract] [Full Text] [Related]

  • 16. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
    Mei W, Wang XM, Liu RA, Xiong W, Zhang YP.
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr 20; 42(4):258-267. PubMed ID: 38677988
    [Abstract] [Full Text] [Related]

  • 17. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.
    J Thorac Oncol; 2017 Sep 20; 12(9):1421-1433. PubMed ID: 28629895
    [Abstract] [Full Text] [Related]

  • 18. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
    Williams M, Kirschner MB, Cheng YY, Hanh J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJ, Vallely MP, McCaughan BC, Cooper W, Klebe S, Lin RC, Brahmbhatt H, MacDiarmid J, van Zandwijk N, Reid G.
    Oncotarget; 2015 Sep 15; 6(27):23480-95. PubMed ID: 26125439
    [Abstract] [Full Text] [Related]

  • 19. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
    Edakuni N, Ikuta K, Yano S, Nakataki E, Muguruma H, Uehara H, Tani M, Yokota J, Aizawa H, Sone S.
    Oncol Res; 2006 Sep 15; 16(5):235-43. PubMed ID: 17294804
    [Abstract] [Full Text] [Related]

  • 20. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E, Giacomino A, Martinetto F, Morone S, Lo Buono N, Ferrero E, Scagliotti G, Novello S, Orecchia S, Ruffini E, Rapa I, Righi L, Volante M, Funaro A.
    Oncotarget; 2014 Aug 15; 5(15):6191-205. PubMed ID: 25026285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.